IMU

0.00%

4.8¢ imugene limited

Media Thread, page-11844

First 11844 Last

Share
Profile

Follow
eztrang

4,179 Posts.

301

12/02/24

19:56

Post #: 72367554
Share

Originally posted by Taureanbull: ↑

Good morning Gajet,

I haven’t been ignoring your question, it’s just a difficult question to answer. Very thought provoking. But after a great morning walk on the beach watching the sunrise, I think I’ve got an answer that makes sense!

Firstly I’ll bring up why I’ve come to my conclusions.

At this point I’m 100% confident in the following points.
1. Yuman Fong has created the greatest cancer treatment ever invented. CF33 is working exactly how he said it would.
2. LC has brought together a world class team to support her amazing talents to shepherd our drug’s through to commercialisation. Taking them to the bedside.
3. PH has steered this company through the very bad storm that has been pounding biotechs for more than 3 years now! Creating the best portfolio of cancer drugs on the planet. And enough cash to get there.

How do I know this? Many years of research and experience both as an investor and a company director in my own private ventures. It’s called experience.

Unfortunately is very expensive. But that’s another story.

I’ve been waiting for a bombshell announcement to trigger a big rerate here. As ZIOR posted a rerate might be a bombshell or very subtle. It’s looking like subtle is the way forward. Just a simple raising of awareness and confidence in our company. Once the Shareprice starts running and 500 new experts turn up here with there first post, we’ll know IMU is on its way. Sadly this forum will go to s**t again like it did on the run up to .63 and down ti .039.

So my answer to your question. Luckily the current market cap of IMU is US$500 so that makes my calculations very simple. My timeline is 12 months. And this also ties in nicely with ZIOR’s charting posts. Which I’ve taken some time to analyse and understand.

The markets always overshoot hence we got .63 and .039. I missed selling at the top but learned my lesson at the bottom and doubled up my position.

As of now I see a minimum MC of US$20Bn. That’s $4.20 per share. Allowing for exuberance $5 to $8. The data will all be released by this time next year to support this MC.

Adding to that excitement we could very likely see a deal signed off. Maybe several deals. And IMU announcing NASDAQ listing .

As for the type of deal , if we see a Roche/Genentech style deal , I would expect to double or even triple my expectations.

It might sound crazy but those returns will be my rewards for 6 years of super high risk investment and diligence in following the science and management very closely. Close enough to have the conviction to invest a substantial amount of my hard earned money in chasing the holy grail of medicine . And cancer is the biggest game of them all.

IMUGENE has got this!

Expand

TB, you say, 100% "Yuman Fong has created the greatest cancer treatment ever invented".
How many different treatments have you evaluated before coming to this conclusion?
What are the #2 and #3 greatest treatments? What criteria do you use in your evaluations?

IMU Price at posting: 11.0¢ Sentiment: Hold Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

BUX

Buxton projects new graphite province discovery at WA Narryer play

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

There are more pages in this discussion • 3,861 more messages in this thread...

First 11844 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 4.8¢		Change 0.000(0.00%)		Mkt cap ! $356.9M

Open	High	Low	Value	Volume
4.9¢	4.9¢	4.8¢	$328.5K	6.792M

Buyers (Bids)

No.	Vol.	Price($)
45	5443565	4.8¢

Sellers (Offers)

Price($)	Vol.	No.
4.9¢	2171910	5

View Market Depth

No.	Vol.	Price($)
45	5443565	0.048
43	4562182	0.047
49	3188200	0.046
61	6392230	0.045
12	2001364	0.044

Price($)	Vol.	No.
0.049	2171910	5
0.050	4756889	17
0.051	6179811	13
0.052	2579418	10
0.053	1158504	8

Last trade - 16.10pm 04/10/2024 (20 minute delay)

IMU (ASX) Chart

Media Thread, page-11844

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Media Thread, page-11844

Top Stories

Buxton projects new graphite province discovery at WA Narryer play

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

BCI reaches close of funding facility for salt-first part of Mardie project

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News